Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Carlsmed (CARL) Cash & Equivalents (2024 - 2025)

Carlsmed's Cash & Equivalents history spans 2 years, with the latest figure at $109.9 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 173.89% year-over-year to $109.9 million; the TTM value through Dec 2025 reached $109.9 million, up 173.89%, while the annual FY2025 figure was $109.9 million, 173.89% up from the prior year.
  • Cash & Equivalents reached $109.9 million in Q4 2025 per CARL's latest filing, down from $115.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $115.4 million in Q3 2025 to a low of $33.5 million in Q2 2025.